This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this collaborative, multi-site (King-Drew Medical Center, Harbor-UCLA Medical Center and Cedars-Sinai Medical Center) study is to examine the predective value of genetic polymorphism in 200 African American and 200 Caucasina subject who meet DSM-IV criteria for major depression when treated with the antidepressant citolopram (CIT). Recent advances in molecular biology and pharmacogenetics have contributed substantially to the understanding of the genetic control of the pharmacogenetics of the cytochrome P-450 enzymes, as well as the neurotransmitter transporters (therapeutic targets of most antidepressants), tools are now available to enable us to systematically response (kalow, 1992; Lin et al., 1993). In order to pursue these goals, this application proposes to contuct a prospective clinical trail of the safety and efficacy of citalopram (Celexa) (CIT), which is the most selective serotonin reuptake inhibitor (SSRI) that is currently available on the U.S. market (Stahl, 1998). CIT biotransformation is mediated pimarilty by CYP2C19 (Catterson & Preskorn, 1996).
Showing the most recent 10 out of 146 publications
